NCT02213926 2026-05-18An Open-label, Phase 2 Study of ACP-196 (Acalabrutinib) in Subjects With Mantle Cell LymphomaAcerta Pharma BVPhase 2 Active not recruiting124 enrolled 10 charts 1 FDA